

MARKSANS PHARMA LIMITED [formerly Tasc Pharmaceuticals Ltd.]
Regd. Office: 601-622, Chintamani Plaza, Mohan Studio Compd, A.K.Road, Andheri [East], Mumbai-400099
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2006

(Rs. In lacs)

Sr. No.	PARTICULARS	Quarter ended		Year ended
		30th June 06 (UNAUDITED)	30th June 05 (UNAUDITED)	31st March 06 (AUDITED)
1	Net sales /Income from Operations	7,044.84	8,287.89	29,185.45
2	Other Income	275.26	39.99	471.17
3	Total Expenditure	6,130.05	6,743.23	24,685.36
	-(Increase) /Decrease in Stock in trade	(432.67)	715.45	(2,355.44)
	-Raw Material cost / consumption	5,400.22	5,048.93	22,648.37
	-Staff Cost	222.26	199.57	947.11
	-Other Expenditure	940.24	779.28	3,445.32
4	Interest	253.95	315.45	1,035.08
5	Depreciation	213.19	175.35	803.98
6	Profit/(Loss) before Tax	722.91	1,093.85	3,132.20
7	Provision for Taxation	145.00	105.23	814.24
8	Net Profit /(Loss) after tax	577.91	988.62	2,317.96
9	Add/Less :Short provision/ Prior period expenses		0.00	29.53
10	Net Profit/(after extra ordinary items	577.91	988.62	2,288.43
11	Paid up Equity Share Capital (Face value Rs. 10 per share)	3,594.06	3,594.06	3,594.06
12	Reserves and Surplus (Excluding Revaluation Reserve)	-		
13	Basic and Diluted EPS for the period (Not annualised)	1.61	2.75	6.37
14	Non -Promoter share holding			
	-Number of Shares	18778527	8903000	18778569
	-Percentage of Share holding	52.25%	71.22%	52.25%

Notes:

- The above results were taken on records at the meeting of the Board of Directors held on 31-07-2006
- The details of investor complaints during the quarter is as under:
Opening Balance : NIL, Received during the quarter :2, Pending as on 30.06.06 : NIL
- The company will consider the effect of deferred tax asset/liability (AS- 22) in the audited accounts at the year end.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

For Marksans Pharma Limited

Place: Mumbai

Date: 31st July, 2006

Mark Saldanha
Chairman & Managing Director